btk

The quick read

What's driving the attention

BTK, a protein targeted by new drugs, is gaining attention due to advancements and investments in treatments for diseases like CLL, SLL, and multiple sclerosis.

BTK refers to Bruton’s tyrosine kinase, a protein involved in the immune system and targeted by experimental drugs for conditions such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and progressive multiple sclerosis. Recent articles highlight significant developments including Roche’s $700 million investment in BTK degraders, promising clinical trial results with BTK inhibitor combinations, and ongoing research into treatment discontinuation patterns.